<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="0ae95603-411c-455b-8bb8-8c5b01dac297"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use CYSTARAN<sup>®</sup> safely and effectively. See full prescribing information for CYSTARAN.<br/>
      <br/> CYSTARAN (cysteamine ophthalmic solution) 0.44%, for topical ophthalmic use<br/> Initial U.S. Approval: 1994</title>
   <effectiveTime value="20250430"/>
   <setId root="b98ee838-ed23-42a9-93b5-72579e490fba"/>
   <versionNumber value="23"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="068301431"/>
            <name>Leadiant Biosciences, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="0625f7d0-953e-40c3-9144-5f61d9a49f04"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250430"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54482-020" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>CYSTARAN</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>cysteamine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="6.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="IF1B771SVB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CYSTEAMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5UX2SD1KE2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CYSTEAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54482-020-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20121230"/>
                                    <high value="20210630"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54482-020-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20220225"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA200740" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20121230"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="54482-035" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>CYSTARAN</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>cysteamine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="6.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="IF1B771SVB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CYSTEAMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5UX2SD1KE2" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CYSTEAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="54482-035-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250425"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA200740" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20121230"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="62bf3ea5-60e3-4eef-820f-2e66c5d85378"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>CYSTARAN<sup>®</sup> is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>CYSTARAN is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="666e07af-1159-4070-b2f7-8484d96f7864"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Instill one drop of CYSTARAN in each eye, every waking hour.</paragraph>
                  <paragraph>Do not touch dropper tip to any surface, as this may contaminate the solution.</paragraph>
                  <paragraph>Discard after 1 week of use.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Instill one drop of CYSTARAN in each eye, every waking hour. (<linkHtml href="#S2">2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="66c68e86-265e-4d0d-b449-0386bfe0d76d"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Ophthalmic solution containing 6.5 mg/mL of cysteamine hydrochloride equivalent to 4.4 mg/mL of cysteamine (0.44%).</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ophthalmic solution containing 6.5 mg/mL of cysteamine hydrochloride equivalent to 4.4 mg/mL of cysteamine (0.44%). (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="6cd98075-fa31-4df9-9648-80377811e53e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="36c08ca6-aead-403e-9b71-9efc2be6a34f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>To minimize the risk of contamination, do not touch the dropper tip to any surface.  Keep bottle tightly closed when not in use. (<linkHtml href="#S5.1">5.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="8b61b52e-4e8f-441b-9705-6718713ffa99"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Contamination of Tip and Solution</title>
                     <text>
                        <paragraph>To minimize contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle.  Keep bottle tightly closed when not in use.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="f8c93ca0-830c-4450-858c-98f36d527dd1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Benign Intracranial Hypertension</title>
                     <text>
                        <paragraph>There have been reports of benign intracranial hypertension (or pseudotumor cerebri) associated with oral cysteamine treatment that has resolved with the addition of diuretic therapy.</paragraph>
                        <paragraph>There have also been reports associated with ophthalmic use of cysteamine; however, all of these patients were on concurrent oral cysteamine.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="aa308cc1-c8c8-4dfe-82ba-136c6720e0d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Contact Lens Use</title>
                     <text>
                        <paragraph>CYSTARAN contains benzalkonium chloride, which may be absorbed by soft contact lenses.  Contact lenses should be removed prior to application of solution and may be reinserted 15 minutes following its administration <content styleCode="italics">[see <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="54de7d10-a5bc-4c7a-9bdb-0bc89304ea8b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Topical Ophthalmic Use</title>
                     <text>
                        <paragraph>CYSTARAN is for topical ophthalmic use.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="68b4fb57-0572-4939-874c-947c3319a1fb"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (incidence approximately 10% or greater) are sensitivity to light, redness, eye pain/irritation, headache and visual field defects. (<linkHtml href="#S6">6</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Leadiant Biosciences, Inc. at 1-888-393-4584 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="718e03f7-97de-4141-8c79-75cf42d99b42"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety data described below reflect exposure in controlled clinical trials of six months to 19 years duration in approximately 300 patients.</paragraph>
                        <paragraph>The most frequently reported ocular adverse reactions occurring in ≥10% of patients were sensitivity to light, redness, and eye pain/irritation, headache and visual field defects.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="04179b8c-24ba-4bcf-bf27-b2a0e22b7b13"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="S8.1">
                     <id root="462b770a-3496-4a5d-9f05-d95c12c18987"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="37cc105f-dd57-41c1-9bbc-94d9ecfd6db4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no adequate and well controlled studies of ophthalmic cysteamine in pregnant women to inform any drug associated risks.  Oral administration of cysteamine to pregnant rats throughout the period of organogenesis was teratogenic at doses 86 to 345 times the recommended human ophthalmic dose (based on body surface area) <content styleCode="italics">[see <linkHtml href="#Data">Data</linkHtml>]</content>. CYSTARAN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="b110c5b5-1910-421e-a921-75c340674f32"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="e4832ef5-e194-48b6-913a-3c7c95f078a8"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Teratology studies have been performed in rats at oral doses in the range of 37.5 mg/kg/day to 150 mg/kg/day (86 to 345 times the recommended human ophthalmic dose based on a body surface area) and have revealed cysteamine bitartrate to be teratogenic.  Observed teratogenic findings were intrauterine death, cleft palate, kyphosis, heart ventricular septal defects, microcephaly, exencephaly, and growth deficits.</paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="9c1c2a88-0a36-4399-a0f4-223bfdce704d"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="89776330-0cbb-40ae-9a77-1713aeabaaf8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information regarding the presence of cysteamine in human milk, the effects on the breastfed infants, or the effects on milk production.  Cysteamine administered orally is present in milk of lactating rats.  It is not known whether measurable levels of cysteamine would be present in maternal milk following topical ocular administration of CYSTARAN.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="eebd5deb-962e-4ee2-9591-8ada6b760cb1"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of CYSTARAN (cysteamine ophthalmic solution) 0.44% have been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="97712ad5-6514-456e-986d-939c377c3754"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>When the clinical studies with CYSTARAN were conducted, the reduced life expectancy from cystinosis did not make it possible to include patients in the geriatric age range.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="66474107-957e-409d-81a0-f1e8e32f6b00"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>The effect of renal impairment on the pharmacokinetics of cysteamine following ophthalmic administration of cysteamine ophthalmic solution has not been evaluated because ophthalmic exposure compared to systemic exposure is negligible.  The majority of the patients in the ophthalmic clinical studies are assumed to have had some degree of renal impairment due to their underlying systemic disease.  The total daily ophthalmic dose is less than 2% of the recommended oral daily dose of cysteamine; thus, the systemic exposure following ophthalmic administration is expected to be negligible compared to oral administration.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="9c5ca3e3-a1ff-4086-bcd5-5ea76d6f4b56"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>CYSTARAN is a sterile ophthalmic solution containing 6.5 mg/mL of cysteamine hydrochloride, equivalent to 4.4 mg/mL of cysteamine (0.44%) as the active ingredient.  Cysteamine is a cystine-depleting agent which lowers the cystine content of cells in patients with cystinosis.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Molecular Formula:   C<sub>2</sub>H<sub>7</sub>NS HCl<br/>Molecular Weight:     113.61</paragraph>
                  <paragraph>Each milliliter of CYSTARAN contains:  Active:  cysteamine 4.4 mg (equivalent to cysteamine hydrochloride 6.5 mg); Preservative:  benzalkonium chloride 0.1 mg; Inactive Ingredients: sodium chloride, hydrochloric acid and/or sodium hydroxide (to adjust pH to 4.1-4.5), and purified water.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cystaran-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="c0af91c1-f316-4fe2-aa02-b06c860ce661"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="S12.1">
                     <id root="09b3a761-cc22-4662-b52a-0767958d8c38"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Cysteamine acts as a cystine-depleting agent by converting cystine to cysteine and cysteine-cysteamine mixed disulfides and reduces corneal cystine crystal accumulation.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="026cf8dc-5cdb-45b8-bbac-091f7a89de6c"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The peak plasma concentration of cysteamine following ocular administration of cysteamine ophthalmic solution in humans is unknown, but it is expected to be substantially less than the peak plasma concentration following oral administration of cysteamine bitartrate.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="3992b4c4-07c8-4770-b8be-2f5528fe4020"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="S13.1">
                     <id root="07ec62a7-f712-400c-8a2c-5e94cbee39d0"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="905c5379-1131-48b6-9e10-7bf03eef8e74"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Cysteamine has not been tested for its carcinogenic potential in long-term animal studies.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="733cfd75-449d-46bf-9c10-5212d7e0772a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Cysteamine was not mutagenic in the Ames test. It produced a negative response in an <content styleCode="italics">in vitro</content> sister chromatid exchange assay in human lymphocytes but a positive response in a similar assay in hamster ovarian cells.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="fb16c5bc-a7ab-4ccb-b666-5d8caf78ce14"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Repeat breeding reproduction studies were conducted in male and female rats.  Cysteamine was found to have no effect on fertility and reproductive performance at an oral dose of 75 mg/kg/day (173 times the recommended human ophthalmic dose based on body surface area).  At an oral dose of 375 mg/kg/day (864 times the recommended human ophthalmic dose based on body surface area), it reduced the fertility of the adult rats and the survival of their offspring.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="6b03bfc3-d6af-45ab-95bd-45b46ea91a28"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>Clinical efficacy was evaluated in controlled clinical trials in approximately 300 patients.  The primary efficacy end point was the response rate of eyes that had a reduction of at least 1 unit in the photo-rated Corneal Cystine Crystal Score (CCCS) at some time point during the study when baseline CCCS ≥1, or a lack of an increase of more than 1 unit in CCCS throughout the study when baseline CCCS &lt;1.</paragraph>
                  <paragraph>Study 1 combined the data from three smaller studies. For eyes with a lower baseline of CCCS &lt;1, the response rate was 13% (4/30) [95% CI: (4, 32)]. For eyes with a higher baseline of CCCS ≥1, the response rate was 32% (94/291) [95% CI: (27, 38)].</paragraph>
                  <paragraph>Study 2 evaluated ocular cystinosis patients who had a baseline of CCCS ≥1.  The response rate was 67% (10/15) [95% CI: (38, 88)].</paragraph>
                  <paragraph>Study 3 also evaluated ocular cystinosis patients; for eyes with a baseline of CCCS ≥1, the response rate was 33% (3/9) [95% CI: (8, 70)].</paragraph>
                  <paragraph>Corneal crystals accumulate if CYSTARAN is discontinued.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="2cdb3392-fed9-44dc-bf47-977a58ea027f"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Fifteen (15) mL of CYSTARAN (cysteamine ophthalmic solution) 0.44% is supplied in an opaque, white, low-density polyethylene (LDPE) 88 mm tall bottle with a 1.6 mm blue, silicone rubber flow-controlled dropper tip and closed with a white, high-density polyethylene (HDPE) screw cap. The bottle is foil-wrapped and stored in a carton.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <section>
                     <id root="b36b8461-fb22-41d4-a217-38d39f1378cb"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>CYSTARAN bottles must be stored in the following conditions:</paragraph>
                        <paragraph>NDC 54482-<content styleCode="bold">020</content>-02</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption> </caption>
                              <content styleCode="bold">Before Opening:</content> Store unopened bottle in freezer at -25°C to -15°C (-13°F to 5°F) in the original packaging including unopened foil. Thaw for approximately 24 hours before use.</item>
                           <item>
                              <caption> </caption>Open the carton and the foil only when starting a new bottle.</item>
                           <item>
                              <caption> </caption>
                              <content styleCode="bold">After Opening:</content> Record discard date on the bottle, which is 1 week from the day the foil and bottle were opened. Store thawed bottle at 2°C to 25°C (36°F to 77°F) for up to 1 week. The thawed bottle does not require refrigeration between use. Do not refreeze the thawed medication. Discard 1 week after the foil and bottle were opened even if there is medication left in the bottle.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="59650ec6-549c-4431-8790-154251ed873d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>NDC 54482-<content styleCode="bold">035</content>-02</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption> </caption>
                              <content styleCode="bold">Before Opening:</content> Store unopened bottle in refrigerator at 2°C to 8°C (36°F to 46°F) in the original packaging including unopened foil.</item>
                           <item>
                              <caption> </caption>Open the carton and the foil only when starting a new bottle.</item>
                           <item>
                              <caption> </caption>
                              <content styleCode="bold">After Opening:</content> Record discard date on the bottle, which is 1 week from the day the foil and bottle were opened. During the week of use, store bottle at room temperature, 20°C to 25°C (68°F to 77°F). Discard 1 week after the foil and bottle were opened even if there is medication left in the bottle.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="5fae5a8a-e282-41d5-a9a9-ee83554b0cf0"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section>
                     <id root="2f53b255-3e4b-49f5-a7c8-c0b855cf3216"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage of Cystaran Bottles NDC 54482-<content styleCode="bold">020</content>-02</content>
                        </paragraph>
                        <list listType="ordered" styleCode="Arabic">
                           <item>Patients should be advised to store unopened bottles in the freezer in the intact foil pouch and original carton.</item>
                           <item>Each week, one new bottle should be removed from the freezer.</item>
                           <item>Patients should be advised to allow the bottle to thaw completely (approximately 24 hours) prior to use.</item>
                           <item>After the bottle is completely thawed, the patient should be advised to open the packaging (carton and foil) and record the discard date on the bottle label. The discard date is seven (7) days from the day the foil and bottle were opened.</item>
                           <item>During the week of use, patients should be advised to store thawed bottle at 2°C to 25°C (36°F to 77°F) for up to 1 week. The thawed bottle does not require refrigeration between use and should not be refrozen.</item>
                           <item>At the end of 1 week (7 days), patients should discard the bottle. There may be medication left in the bottle; however, the bottle must be discarded by the patient because the medication is only stable for 1 week after the foil and bottle were opened.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ed55efe9-7085-48a5-932f-5af490ea2b60"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage of Cystaran Bottles NDC 54482-<content styleCode="bold">035</content>-02</content>
                        </paragraph>
                        <list listType="ordered" styleCode="Arabic">
                           <item>Patients should be advised to store unopened bottles in the refrigerator in the intact foil pouch and original carton.</item>
                           <item>When starting a new bottle, patients should be advised to open the packaging (carton and foil) and record the discard date on the bottle label. The discard date is seven (7) days from the day the foil and bottle were opened.</item>
                           <item>During the week of use, patients should be advised to store the bottle at room temperature 20°C to 25°C (68°F to 77°F) for up to 1 week.</item>
                           <item>At the end of 1 week (7 days), patients should discard the bottle. There may be medication left in the bottle; however, the bottle must be discarded by the patient because the medication is only stable for 1 week after the foil and bottle were opened.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b9393026-2b06-4130-8022-fed7a58b9556"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk of Contamination</content>
                        </paragraph>
                        <paragraph>Patients should be advised not to touch the eyelid or surrounding areas with the dropper tip of the bottle.  The cap should remain on the bottle when not in use.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5826ae68-ccbe-46e5-86ad-eba9b922c79c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Use with Contact Lenses</content>
                        </paragraph>
                        <paragraph>Patients should be advised that contact lenses should be removed prior to application of CYSTARAN.  Contact lenses may be reinserted 15 minutes following CYSTARAN administration.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="de7ede90-760a-4c15-b766-1d63f1fb904b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Topical Ophthalmic Use </content>
                        </paragraph>
                        <paragraph>Patients should be advised that CYSTARAN is for topical ophthalmic use.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="a3c3652c-8b38-42cf-8e6e-8a9a4e80b2c7"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>CYSTARAN (cysteamine ophthalmic solution) 0.44% is distributed by Leadiant Biosciences, Inc., Rockville, MD 20850.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>
                  <paragraph>cyspi-6-m</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cystaran-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="34775ca6-8c3c-4cb4-9785-0222463275e9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 15 mL Bottle Carton</title>
               <text>
                  <paragraph>NDC 54482-<content styleCode="bold">020</content>-02</paragraph>
                  <paragraph>cystaran<sup>®</sup>
                  </paragraph>
                  <paragraph>(cysteamine ophthalmic<br/>solution) 0.44%</paragraph>
                  <paragraph>
                     <content styleCode="bold">For Topical Ophthalmic Use</content>
                  </paragraph>
                  <paragraph>Sterile</paragraph>
                  <paragraph>15 mL</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>
                     <content styleCode="bold">Active Ingredient:</content> Each mL<br/>contains 6.5 mg cysteamine<br/>hydrochloride, equivalent to<br/> 4.4 mg cysteamine. <content styleCode="bold">Inactive<br/> Ingredients:</content> Benzalkonium<br/> chloride (preservative); Sodium<br/> chloride; hydrochloric acid<br/> and/or sodium hydroxide (to<br/> adjust pH) and purified water.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dosage:</content> See Prescribing<br/> Information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage:</content> Store in freezer in<br/> original carton at -25°C to -15°C<br/> (-13°F to 5°F). Thaw in original<br/> carton for approximately 24<br/> hours before use. Store thawed<br/> bottle at 2°C to 25°C (36°F to<br/> 77°F) for up to 1 week. Do not<br/> refreeze thawed medication.<br/>
                     <content styleCode="bold">Discard after 1 week of use,<br/> even if there is remaining drug<br/> product. Avoid touching dropper<br/> tip to any surface.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Topical Ophthalmic Use</content>
                  </paragraph>
                  <paragraph>cysc-6-m</paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Leadiant Biosciences Inc.,</content>
                     <br/>Rockville, MD 20850</paragraph>
                  <paragraph>Made in Switzerland</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 15 mL Bottle Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cystaran-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="9eba1418-2cd0-4c97-988b-8e328496007b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - Carton</title>
               <text>
                  <paragraph>NDC 54482-<content styleCode="bold">035</content>-02</paragraph>
                  <paragraph>
                     <content styleCode="bold">cystaran<sup>®</sup>
                     </content>
                     <br/>(cysteamine ophthalmic<br/>solution) 0.44%</paragraph>
                  <paragraph>
                     <content styleCode="bold">For Topical Ophthalmic Use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NEW STORAGE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">15 mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active Ingredient:</content> Each mL<br/>contains 6.5 mg cysteamine<br/>hydrochloride, equivalent to<br/>4.4 mg cysteamine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive Ingredients:</content> Benzalko-<br/>nium chloride (preservative); <br/>Sodium chloride; hydrochloric <br/>acid and/or sodium hydroxide (to <br/>adjust pH) and purified water.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Dosage:</content> See Prescribing <br/>Information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before Opening:</content> Store in <br/>refrigerator in original packaging, <br/>including unopened foil, at 2°C to <br/>8°C (36°F to 46°F).</paragraph>
                  <paragraph>
                     <content styleCode="bold">After Opening:</content> After opening the <br/>foil, store bottle at room <br/>temperature 20°C to 25°C (68°F <br/>to 77°F) during week of use.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Discard the bottle 1 week after <br/>opening the foil and bottle, even <br/>if there is remaining medication <br/>in the bottle. Avoid touching <br/>dropper tip to any surface.</content>
                  </paragraph>
                  <paragraph>cysc-7-m</paragraph>
                  <paragraph>Distributed by: <br/>
                     <content styleCode="bold">Leadiant Biosciences, Inc.</content>,<br/>Rockville, MD 20850</paragraph>
                  <paragraph>Made in Switzerland</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PRINCIPAL DISPLAY PANEL - Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="cystaran-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>